ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30-35 kg/m²)

Surg Obes Relat Dis. 2018 Aug;14(8):1071-1087. doi: 10.1016/j.soard.2018.05.025. Epub 2018 Jun 9.

Authors

Ali Aminian¹, Julietta Chang², Stacy A Brethauer², Julie J Kim³; American Society for Metabolic and Bariatric Surgery Clinical Issues Committee

Affiliations

¹ Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio. Electronic address: aminiaa@ccf.org.
² Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio.
³ Harvard Medical School, Mount Auburn Hospital, Cambridge, Massachusetts.

PMID: 30061070
DOI: 10.1016/j.soard.2018.05.025

No abstract available

Publication types

Review

MeSH terms

Anti-Obesity Agents / therapeutic use
Bariatric Surgery* / adverse effects
Bariatric Surgery* / statistics & numerical data
Humans
Obesity, Morbid / drug therapy
Obesity, Morbid / economics
Obesity, Morbid / epidemiology*
Obesity, Morbid / surgery*
Risk Assessment
Societies, Medical
United States / epidemiology

Substances

Anti-Obesity Agents